retatrutide approval 2025 UK Guide: Key Facts on the New Weight-Loss Drug retatrutide approval status october 2025

If that sounds familiar, youre not alone

After Ozempic, the market is moving toward obesity-specific injectables, oral GLP-1 drugs, dual agonists, triple agonists, amylin combinations, and cardiometabolic platform therapies

[DOI] [PMC free article] [PubMed] [Google Scholar] 22

This finding is consistent with the hypothesis that incretin signalling at GLP-1R and GIPR functionally counterbalances the glucagonergic input under high-glucose conditions

Even a minor mistake can stall production

Terushkin provides virtual consultations for patients interested in Wegovy and Ozempic, making it easier for individuals across South Florida to access these treatments